Concerns & Barriers Around Real-World Data Adoption
At Inteliquet, we partner with Life Sciences and help reduce the barriers and time involved in clinical research. We recently conducted a survey to examine real-world data (RWD) adoption.
Since the adoption is moving rapidly, we wanted to hear the latest thinking from Pharma, Biopharma, MedTech, and Medical Device company executives, as well as those from Contract Research Organizations (CROs). Here’s a brief overview of what we found.
1. Accumulating data is not a significant problem; accumulating the right data is.
Although the industry is rapidly adopting RWD, significant barriers and challenges remain to accessing the right kind of current primary patient data. Not all data is the best data when it comes to providing proper analytics and insight. Organizations surveyed said that they struggle with:
- Accessing robust data (cited by 44 percent of respondents).
- Accessing primary patient journey data (39 percent).
- Gaining internal knowledge/understanding of where RWD/RWE analyses can be applied (37 percent).
As organizations grapple with quality data and complex digital analytics, they will see a deleterious effect on the analysis. It is vital to use the right data at the beginning of the process to achieve the best outcomes—from preplanning and trial design to selecting clinical sites with patient populations that provide the best chances to enroll the study.
2. Even with these concerns, many use RWD in numerous areas today.
A significant majority of respondents (91 percent) report they currently use RWD in clinical development and decision-making, and 84 percent have internal systems to capture and analyze RWD. They also noted its use in:
- Clinical trial designs (65 percent of respondents).
- Early R&D preclinical planning (52 percent).
- Clinical development (52 percent).
- Post-market observational studies (50 percent).
Even the best technology in the world will fail without proper data—that are specific, relevant, and timely. As organizations devote more resources to RWD, it is important to better organize and validate data to improve its RWE utility in our highly regulated industry. RWD must reflect the reality on the ground or the challenges we discovered in the course of this survey will become exponentially worse.
3. Organizations will be devoting more resources to RWD this year.
The survey found that:
- 89 percent of organizations plan to grow their budgets in 2020.
- Two-thirds (66 percent) said they will increase their budgets by 20 percent or more.
- Nearly half (46 percent) said their budgets will increase by more than 40 percent.
- At least 53 percent said that they already allocate more than $100,000 per year to RWD.
Given the promise of RWD/RWE and the increasingly robust data sets that are becoming available, we expect this growth to continue. It makes finding the right data more important as organizations continue to invest aggressively.
4. RWD will “go mobile.”
The types of data that respondents said they want to use more aggressively in the future include the following:
- 67 percent of respondents said they see value in accessing data from mobile devices, social media, health apps, wearables, or other biometric devices, although only 49 percent currently use this data source.
- 47 percent of respondents are considering using genomic data and markers more aggressively in the future, compared with just 39 percent who currently use it.
As clinical trials become more patient-centric, mobile tools could increasingly play a role in oncology by helping to monitor and manage side effects, as well as other applications. Such tools can help improve the personal experiences of clinical trial participants.
HOW NEW THERAPIES REACH PATIENTS FASTER